EPS Bio Technology (4183) Monthly Revenue

Market: TPEx (OTC) · Industry: Biotech & Medical · 福永生技

EPS Bio Technology (4183) reported revenue of NT$12.6 million for Oct 2026, -72.1% year on year and -63.3% from the previous month. Revenue for Jan–Oct 2026 was NT$273.7 million (-35.7% year on year).

In Oct 2026, it ranked No. 130 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$14.4 million24/10Nov 2024 NT$49.2 millionDec 2024 NT$53.1 millionJan 2025 NT$36.8 millionFeb 2025 NT$29.7 million25/02Mar 2025 NT$53.7 millionApr 2025 NT$36.5 millionMay 2025 NT$58.6 millionJun 2025 NT$34.6 million25/06Jul 2025 NT$41.8 millionAug 2025 NT$39.2 millionSep 2025 NT$49.6 millionOct 2025 NT$45 million25/10Nov 2025 NT$30.1 millionDec 2025 NT$44.1 millionJan 2026 NT$27.5 millionFeb 2026 NT$17 million26/02Mar 2026 NT$18.9 millionApr 2026 NT$28.3 millionMay 2026 NT$40.4 millionJun 2026 NT$36.8 million26/06Jul 2026 NT$26.2 millionAug 2026 NT$31.7 millionSep 2026 NT$34.2 millionOct 2026 NT$12.6 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$12.6 million-72.1%-63.3%
Sep 2026NT$34.2 million-31.0%+8.0%
Aug 2026NT$31.7 million-19.1%+20.8%
Jul 2026NT$26.2 million-37.2%-28.8%
Jun 2026NT$36.8 million+6.4%-8.9%
May 2026NT$40.4 million-30.9%+42.9%
Apr 2026NT$28.3 million-22.6%+50.0%
Mar 2026NT$18.9 million-64.8%+11.0%
Feb 2026NT$17 million-42.8%-38.2%
Jan 2026NT$27.5 million-25.3%-37.6%
Dec 2025NT$44.1 million-16.9%+46.5%
Nov 2025NT$30.1 million-38.8%-33.1%
Oct 2025NT$45 million+212.2%-9.3%
Sep 2025NT$49.6 million-10.8%+26.7%
Aug 2025NT$39.2 million+174.3%-6.2%
Jul 2025NT$41.8 million+26.9%+20.6%
Jun 2025NT$34.6 million-33.7%-40.9%
May 2025NT$58.6 million+4.4%+60.3%
Apr 2025NT$36.5 million+44.4%-31.9%
Mar 2025NT$53.7 million-1.9%+80.5%
Feb 2025NT$29.7 million+25.0%-19.3%
Jan 2025NT$36.8 million+89.1%-30.7%
Dec 2024NT$53.1 million+83.6%+8.0%
Nov 2024NT$49.2 million-18.5%+241.3%
Oct 2024NT$14.4 million-76.5%-74.1%

Jan–Oct 2026 cumulative: NT$273.7 million (-35.7% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: EPS Bio Technology vs PEC / EPS Bio Technology vs Lotus Pharm / EPS Bio Technology vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

Company remark (original Chinese)

訂單量減少

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16